KMTS vs BSX

For growth investors, KESTRA MEDICAL TECHNOLOGIES, LTD.

(KMTS) is the stronger pick with 115. 1% revenue growth year-over-year, versus 19. 9% for Boston Scientific Corporation (BSX). Boston Scientific Corporation (BSX) offers the better valuation at 29. 2x trailing P/E (16. 7x forward), making it the more compelling value choice. Analysts rate KESTRA MEDICAL TECHNOLOGIES, LTD. (KMTS) a "Buy" — based on 4 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

Over the past 5 years, Boston Scientific Corporation (BSX) delivered a total return of +31.

2%, compared to -1. 5% for KESTRA MEDICAL TECHNOLOGIES, LTD. (KMTS). Over 10 years, the gap is even starker: BSX returned +155. 5% versus KMTS's -1. 5%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Boston Scientific Corporation (BSX) is the lower-risk stock at 0.

34β versus KESTRA MEDICAL TECHNOLOGIES, LTD. 's 1. 87β — meaning KMTS is approximately 445% more volatile than BSX relative to the S&P 500. On balance sheet safety, KESTRA MEDICAL TECHNOLOGIES, LTD. (KMTS) carries a lower debt/equity ratio of 22% versus 51% for Boston Scientific Corporation — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), KESTRA MEDICAL TECHNOLOGIES, LTD.

(KMTS) is pulling ahead at 115. 1% versus 19. 9% for Boston Scientific Corporation (BSX). On earnings-per-share growth, the picture is similar: Boston Scientific Corporation grew EPS 55. 2% year-over-year, compared to -151. 5% for KESTRA MEDICAL TECHNOLOGIES, LTD.. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Boston Scientific Corporation (BSX) is the more profitable company, earning 14.

4% net margin versus -190. 3% for KESTRA MEDICAL TECHNOLOGIES, LTD. — meaning it keeps 14. 4% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: BSX leads at 19. 8% versus -177. 8% for KMTS. At the gross margin level — before operating expenses — BSX leads at 69. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

Analyst consensus price targets imply the most upside for BSX: 61.

4% to $91. 33.

In this comparison, KMTS (0.

2% yield) pays a dividend. BSX does not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, Boston Scientific Corporation (BSX) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.

34), +155. 5% 10Y return). KESTRA MEDICAL TECHNOLOGIES, LTD. (KMTS) carries a higher beta of 1. 87 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (BSX: +155. 5%, KMTS: -1. 5%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.